Meyer, T <br/><br/>
Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice.  [electronic resource] 

 -  Journal of thrombosis and haemostasis : JTH  Jan 2009 
 - 171-81 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1538-7836 
<br/><br/><label>Standard No.: </label>10.1111/j.1538-7836.2008.03212.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antibodies, Monoclonal--adverse effects<br/>Antibodies, Monoclonal, Humanized<br/>Antigen-Antibody Complex--adverse effects<br/>Bevacizumab<br/>Heparin--physiology<br/>Mice<br/>Mice, Transgenic<br/>Platelet Activation--drug effects<br/>Receptors, IgG--genetics<br/>Thrombosis--chemically induced<br/>Vascular Endothelial Growth Factor A--immunology